ALZpath Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ALZpath's estimated annual revenue is currently $1.2M per year.(i)
  • ALZpath's estimated revenue per employee is $77,500

Employee Data

  • ALZpath has 15 Employees.(i)
  • ALZpath grew their employee count by 15% last year.

ALZpath's People

NameTitleEmail/Phone
1
Co-Founder, CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Chief Business OfficerReveal Email/Phone
4
VP FinanceReveal Email/Phone
5
Senior Scientific Program ManagerReveal Email/Phone
6
Executive Assistant to the CEO, CSO and CBOReveal Email/Phone
7
Senior Principal Scientist, BiomarkersReveal Email/Phone
8
Medical Science LiaisonReveal Email/Phone
9
Digital DesignerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is ALZpath?

ALZpath is a passionate and focused group of medical researchers, healthcare professionals, and renowned group of scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem through earlier diagnosis, interventions, and personalized treatment to improve outcomes for people with Alzheimer’s.Launching a novel blood-based biomarker assay for phosphorylated tau 217 (ptau217), ALZpath offers a simple, accessible, timely, and cost-effective approach to diagnosis, which is less invasive than current testing methods. Ptau217 in blood is considered one of the transformative AD diagnostic biomarker, which closely reflects amyloid and tau pathology, the hallmarks of AD, and associates with clinical features of AD.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$1.2M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.3M1515%N/A
#2
$1.9M15-12%N/A
#3
$2.1M1550%N/A
#4
$2.3M1567%N/A
#5
$0.9M15-6%N/A